San Diego, California–(Newsfile Corp. – July 3, 2022) – Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors’ losses and whether they may be recovered under the federal securities laws.
What if I purchased Enochian common stock? If you purchased Enochian common stock and suffered significant losses on your investment, join our investigation now:
Click or paste the following web address into your browser to submit your losses: https://www.johnsonfistel.com/investigations/enochian-biosciences-inc-murder-sec-class-action
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On May 25, 2022, the United State Attorney’s Office for the District of Vermont, announced that the co-founder of Enochian Biosciences Inc was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018. Dr. Serhat Gumrukcu, a co-founder of Enochian Biosciences, is being charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire, which resulted in the death of Gregory Davis, a resident of Vermont.
Dr. Gumrukcu sold 253,493 shares of Enochian Biosciences stock on May 18, 2022, for a total value of over $2 million.
Then, on June 1, 2022, market analyst Hindenburg Research published a report regarding Enochian titled “Miracle Cures and Murder For Hire: How A Spoon-Bending Turkish Magician Built A $600 Million Nasdaq-Listed Scam Based On A Lifetime Of Lies[.]” The report noted that the individual in whose murder Gumrukçu was implicated, Gregory Davis, “was murdered … just 19 days before Gumrukcu was scheduled to appear in court to defend himself against felony fraud allegations related to a 2016 deal with Davis” and that “[f]ederal prosecutors argued that the prospective merger deal that eventually resulted in Enochian going public served as a key motive for the murder.” The report also stated that “[u]nbeknownst to investors (but known to Enochian’s senior leadership) Gumrukcu’s latest arrest for a murder conspiracy is simply the most recent in a string of alleged crimes by Gumrukcu,” who “was arrested based on accusations of falsely posing as a doctor” in his native Turkey in 2012 and “[i]n February 2017, Gumrukcu was arrested by authorities after the State of California accused him of a slew of white-collar crimes, including fraud, identity theft, and check kiting – a total of 14 felonies.” The report further states that “[w]e have been unable to find any jurisdiction in which Gumrukcu is licensed as a medical doctor” and that “Gumrukcu looks to have purchased a fake Russian medical degree on the black market[.]”
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or [email protected].
About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129852